文献速递肿瘤 PET/CT

晚期非小细胞肺癌患者中18F-BMS-986192 PET/CT对PD-L1表达的定量

Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
PubMed 文献 · J Nucl Med · 2020-02-14

本研究对9例晚期非小细胞肺癌患者行18F-BMS-986192动态PET/CT,采用动脉血浆输入动力学模型定量肿瘤摄取,共分析22个肿瘤。单组织可逆隔室模型拟合最佳,分布体积VT为0.4–4.8 mL·cm-3,注射后50和67分钟体重归一化SUV与VT相关性最佳(R2>0.9)。作者认为体重归一化60分钟SUV是基线研究的准确简化参数,并建议进一步验证其预测价值。

要点

  • 单组织可逆隔室模型可定量PD-L1示踪剂18F-BMS-986192的肿瘤摄取。
  • 注射后50和67分钟体重归一化SUV与VT相关性最佳,R2>0.9。
  • 作者建议进一步验证SUV对免疫检查点抑制剂疗效的预测价值。

核心结论

  • 单组织可逆模型可用于定量PD-L1 PET示踪剂18F-BMS-986192的肿瘤摄取。
  • 注射后60分钟体重归一化SUV是基线研究摄取评估的准确简化参数。
  • 作者建议基于图像衍生输入函数进一步验证SUV相对于VT的预测价值,以评估程序性细胞死亡蛋白1或PD-L1免疫检查点抑制的疗效。

研究设计与样本

  • 研究纳入接受纳武利尤单抗治疗的晚期非小细胞肺癌患者,仅分析有动态扫描且动态扫描视野内存在病灶者。
  • 注射18F-BMS-986192后先行60分钟动态PET/CT,随后行30分钟全身PET/CT。
  • 行动脉连续采血及离散动脉和静脉采血以确定血浆输入函数,肿瘤时间-活性曲线用多种血浆输入动力学模型拟合。
  • 共分析9例患者的22个肿瘤。

主要发现

  • 动脉血浆输入单组织可逆隔室模型(拟合血容量分数)最佳拟合18条肿瘤时间-活性曲线中的11条,为最受青睐的模型。
  • 分布体积VT范围为0.4至4.8 mL·cm-3,采用图像衍生输入函数获得相似数值。
  • 简化参数中,注射后50和67分钟体重归一化SUV与VT相关性最佳,R2大于0.9。

局限性

  • 作者建议进一步验证基于图像衍生输入函数的SUV相对于VT的预测价值,以评估程序性细胞死亡蛋白1或PD-L1免疫检查点抑制的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this work was to quantify the uptake of 18F-BMS-986192, a programmed cell death ligand 1 (PD-L1) adnectin PET tracer, in patients with non-small cell lung cancer. To this end, plasma input kinetic modeling of dynamic tumor uptake data with online arterial blood sampling was performed. In addition, the accuracy of simplified uptake metrics such as SUV was investigated. Methods: Data from a study with 18F-BMS-986192 in patients with advanced-stage non-small cell lung cancer eligible for nivolumab treatment were used if a dynamic scan was available and lesions were present in the field of view of the dynamic scan. After injection of 18F-BMS-986192, a 60-min dynamic PET/CT scan was started, followed by a 30-min whole-body PET/CT scan. Continuous arterial and discrete arterial and venous blood sampling were performed to determine a plasma input function. Tumor time-activity curves were fitted by several plasma input kinetic models. Simplified uptake parameters included tumor-to-blood ratio as well as several SUV measures. Results: Twenty-two tumors in 9 patients were analyzed. The arterial plasma input single-tissue reversible compartment model with fitted blood volume fraction seems to be the most preferred model as it best fitted 11 of 18 tumor time-activity curves. The distribution volume (VT ) ranged from 0.4 to 4.8 mL⋅cm-3 Similar values were obtained with an image-derived input function. From the simplified measures, SUV normalized for body weight at 50 and 67 min after injection correlated best with VT , with an R2 of more than 0.9. Conclusion: A single-tissue reversible model can be used to quantify tumor uptake of the PD-L1 PET tracer 18F-BMS-986192. SUV at 60 min after injection, normalized for body weight, is an accurate simplified parameter for uptake assessment of baseline studies. To assess its predictive value for response evaluation during programmed cell death protein 1 or PD-L1 immune checkpoint inhibition, further validation of SUV against VT based on an image-derived input function is recommended.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Huisman MC, Niemeijer AN, Windhorst AD, et al. Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer. J Nucl Med. 2020. PMID: 32060213. doi:10.2967/jnumed.119.240895

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。